SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001326190-23-000044
Filing Date
2023-11-07
Accepted
2023-11-07 07:06:41
Documents
14
Period of Report
2023-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alt-20231107x8k.htm   iXBRL 8-K 43152
2 EX-99.1 alt-20231107xex99d1.htm EX-99.1 171667
3 GRAPHIC alt-20231107xex99d1002.jpg GRAPHIC 7092
  Complete submission text file 0001326190-23-000044.txt   359513

Data Files

Seq Description Document Type Size
4 EX-101.SCH alt-20231107.xsd EX-101.SCH 3135
5 EX-101.LAB alt-20231107_lab.xml EX-101.LAB 15903
6 EX-101.PRE alt-20231107_pre.xml EX-101.PRE 10116
8 EXTRACTED XBRL INSTANCE DOCUMENT alt-20231107x8k_htm.xml XML 4868
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Filer) CIK: 0001326190 (see all company filings)

IRS No.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32587 | Film No.: 231381519
SIC: 2834 Pharmaceutical Preparations